Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CBP-174

Other · developed by Connect Biopharma Australia Pty

Phase 1 Most advanced trial (none active)
CNTB Developer
1 Registered trials

What is CBP-174?

CBP-174 is an oral solution given once.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Developer
Connect Biopharma Australia Pty Ltd (CNTB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04811469 Phase 1 Healthy Adult Subjects Completed CNTB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Adult Subjects

More from Connect Biopharma Australia Pty

CBP-201 Phase 3 CBP-307 Phase 2 Rademikibart Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CNTB page.

Follow CNTB, the company behind CBP-174

See CNTB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CNTB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.